🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

455 results for “60” Clear

  1. A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.

    GlaxoSmithKline Biologicals S.A.

    Neoplasms, Colorectal

    phase 2 other active

    1 trial

  2. A Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding, Adaptive Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Narcolepsy without Cataplexy (NT2)

    Takeda Pharmaceuticals International AG

    Narcolepsy without Cataplexy (NT2)

    phase 2 other active

    1 trial

  3. ADCT-602

    ADC Therapeutics SA

    Blasts 5 Percent or More of Bone Marrow Nucleated Cells

    phase 2 mab terminated

    1 trial

  4. ALLO-605

    Allogene Therapeutics

    Relapsed/Refractory Multiple Myeloma

    phase 2 gene therapy terminated

    1 trial

  5. ALX-0600

    Takeda Pharmaceuticals International AG

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  6. AMGLIDIA 6 mg/mL oral suspension

    Pari Pharma GmbH

    Transient hyperglycaemia in premature infants

    phase 2 small molecule active

    1 trial

  7. AZD4360

    AstraZeneca AB

    Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  8. AZD4604, AZD4604 Placebo, AZD4604

    AstraZeneca AB

    Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

    phase 2 small molecule active

    1 trial

  9. AZD4604, Azd4604 placebo, AZD4604

    AstraZeneca AB

    Asthma

    phase 2 small molecule active

    1 trial

  10. AZD5004, Placebo to match AZD5004 film coated tablet, AZD5004, AZD5004

    AstraZeneca AB

    Participants living with Obesity or Overweight with at least 1 comorbidity

    phase 2 small molecule active

    1 trial

  11. AZD6793, AZD6793 Placebo, AZD6793, AZD6793

    AstraZeneca AB

    Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

    phase 2 small molecule active

    1 trial

  12. Abraxane 5 mg/ml powder for dispersion for infusion., Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, RoActemra 20 mg/mL concentrate for solution for infusion, Gemcitabin AqVida 38 mg/ml Pulver zur Herstellung einer Infusionslösung, Gemcitabin Kabi 38 mg/ml Pulver zur Herstellung einer Infusionslösung, Avastin 25 mg/ml concentrate for solution for infusion., ATEZOLIZUMAB, Tiragolumab

    Roche Registration Limited

    Pancreatic ductal adenocarcinoma (PDAC)

    phase 2 small molecule active

    1 trial

  13. Aficamten, Aficamten, Aficamten, Aficamten

    Cytokinetics (Ireland) Limited

    Symptomatic hypertrophic cardiomyopathy (HCM)

    phase 2 small molecule active

    1 trial

  14. Atacicept Autoinjector Combination, Atacicept

    Vera Therapeutics

    Multiple Autoimmune Glomerular Diseases

    phase 2 small molecule active

    1 trial

  15. Avastin 25 mg/ml concentrate for solution for infusion., Lynparza 150 mg film-coated tablets, Cotellic 20 mg film-coated tablets, Ipatasertib, Cotellic, Cotellic, INAVOLISIB, Sindaxel 6 mg/ml concentrat pentru soluţie perfuzabilă, Verzenios 50 mg film-coated tablets, Cotellic, Lynparza 100 mg film-coated tablets, Kadcyla 160 mg powder for concentrate for solution for infusion., LETRO-cell® 2,5 mg Filmtabletten, INAVOLISIB, Verzenios 100 mg film-coated tablets, INAVOLISIB, Lynparza 150 mg film-coated tablets

    Roche Registration Limited

    Persistent or Recurrent Rare Epithelial Ovarian Tumors

    phase 2 small molecule active

    1 trial

  16. BINIMETINIB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB, IPILIMUMAB, ENCORAFENIB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma

    phase 2 small molecule active

    1 trial

  17. BMS-986523, BMS-986523

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Solid Tumor Malignancies

    phase 2 small molecule active

    1 trial

  18. BNT327 50 mg ml, BNT327 20 mg ml, IPILIMUMAB, ATEZOLIZUMAB, ATEZOLIZUMAB, BEVACIZUMAB, Ipilimumab

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced or unresectable Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  19. Bactrim 160 mg + 800 mg compresse, CHLORPHENAMINE MALEATE, ALLOPURINOL, BRUKINSA 80 mg hard capsules, DEXAMETHASONE PHOSPHATE, VENETOCLAX, VENETOCLAX, Gazyvaro 1,000 mg concentrate for solution for infusion., Lamivudina Mylan 150 mg compresse rivestite con film, VENETOCLAX, PARACETAMOL

    Fondazione Telethon ETS

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  20. Balstilimab, CR6086, CR6086

    Pharm Research Associates (UK) Limited

    Pretreated mismatch-repair-proficient and microsatellite stable metastatic colorectal cancer, and other metastatic GI cancers

    phase 2 small molecule active

    1 trial

  21. Braftovi 75 mg hard capsules, Erbitux 5 mg/mL solution for infusion

    CERO THERAPEUTICS HOLDINGS, INC.

    BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER

    phase 2 small molecule active

    1 trial

  22. Braftovi 75 mg hard capsules, Mektovi 15 mg film-coated tablets

    CERO THERAPEUTICS HOLDINGS, INC.

    BRAFV600E-mutant metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  23. Busulfan Koanaa 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, GRANOCYTE 34 Millions UI/ml, poudre et solvant pour solution injectable / perfusion, Autologous CD34+ cells transduced with lentiviral vector encoding the human beta-globin gene, Plerixafor Accord 20 mg/ml solution for injection

    Fondazione Telethon ETS

    transfusion-dependent beta-thalassemia

    phase 2 small molecule active

    1 trial

  24. C4531002-A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of PF-07275315 and PF-07264660 in Adult Participants with Moderate-Severe Atopic Dermatitis.

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Moderate-Severe Atopic Dermatitis

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources